Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dermatological Medicine
Volume 2019, Article ID 6702870, 7 pages
https://doi.org/10.1155/2019/6702870
Case Report

Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with Unusual Manifestations and Review of the Literature

1University of Nevada, School of Medicine, Reno and Las Vegas, Nevada, USA
2Associated Pathologists Chartered, Las Vegas, Nevada, USA
3College of Osteopathic Medicine, Touro University, Henderson, Nevada, USA
4Thomas Dermatology, Las Vegas, Nevada, USA
5University of California, Los Angeles (UCLA), California, USA

Correspondence should be addressed to Narciss Mobini; moc.loa@snocsm

Received 7 May 2019; Revised 16 June 2019; Accepted 25 June 2019; Published 9 July 2019

Academic Editor: Soner Uzun

Copyright © 2019 Narciss Mobini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Hoffman, A. Forschner, C. Loquai et al., “Cutaneous, gastrointestinal, hepatic,endocrine, and renal side-effects of anti-PD-1 therapy,” European Journal of Cancer, vol. 60, pp. 190–209, 2016. View at Google Scholar
  2. M. T. Tetzlaff, A. A. Jazaeri, C. A. Torres-Cabala et al., “Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of two patients,” Journal of Cutaneous Pathology, vol. 44, no. 12, pp. 1080–1086, 2017. View at Publisher · View at Google Scholar
  3. J. L. Curry, M. T. Tetzlaff, P. Nagarajan et al., “Diverse types of dermatologic toxicities from immune checkpoint blockade therapy,” Journal of Cutaneous Pathology, vol. 44, no. 2, pp. 158–176, 2017. View at Publisher · View at Google Scholar
  4. C. M. Cornejo, P. Haun, J. English, and M. Rosenbach, “Immune checkpoint inhibitors and the development of granulomatous reactions,” Journal of the American Academy of Dermatology, 2018. View at Google Scholar
  5. L. K. Collins, M. S. Chapman, J. B. Carter, and F. H. Samie, “Cutaneous adverse effects of the immune checkpoint inhibitors,” Current Problems in Cancer, vol. 41, no. 2, pp. 125–128, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Zimmer, J. Vaubel, E. Livingstone, and D. Schadendorf, “Side effects of systemic oncological therapies in dermatology,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 10, no. 7, pp. 475–486, 2012. View at Publisher · View at Google Scholar
  7. C. J. Voskens, S. M. Goldinger, C. Loquai et al., “The price of tumor control: an analysis of rare side effects of anti-CTLA-4therapy in metastatic melanoma from ipilimumab network,” PLoS One, vol. 8, Article ID e57345, 2013. View at Google Scholar
  8. A. Eckert, A. Schoeffler, S. Dalle, A. Phan, L. Kiakouama, and L. Thomas, “Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient,” Dermatology, vol. 218, no. 1, pp. 69-70, 2009. View at Publisher · View at Google Scholar
  9. K. C. Suozzi, M. Stahl, C. J. Ko et al., “Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy,” JAAD Case Reports, vol. 2, no. 3, pp. 264–268, 2016. View at Publisher · View at Google Scholar
  10. T. Ogawa, Y. Ishitsuka, K. Iwamoto et al., “Programmed cell death 1 blockade-induced cutaneous sarcoid-like epithelioid granulomas in advanced melanoma: a case report,” Journal of the European Academy of Dermatology and Venereology, vol. 32, no. 7, pp. e260–e261, 2018. View at Publisher · View at Google Scholar
  11. M. R. Birnbaum, M. W. Ma, S. Fleisig et al., “Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma,” JAAD Case Reports, vol. 3, no. 3, pp. 208–211, 2017. View at Publisher · View at Google Scholar
  12. F. Dimitriou, A. L. Frauchiger, M. Urosevic-Maiwald et al., “Sarcoid-like reactions in patients receiving modern melanoma treatment,” Melanoma Research, vol. 28, no. 3, pp. 230–236, 2018. View at Publisher · View at Google Scholar
  13. M. T. Tetzlaff, K. C. Nelson, A. Diab et al., “Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients,” Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, p. 14, 2018. View at Publisher · View at Google Scholar
  14. C. Kim, J. Gao, V. R. Shannon, and A. Siefker-Radtke, “Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition,” BMJ Case Reports, vol. 2016, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Sepehri, K. Hutton Carlsen, and J. Serup, “Papulo-nodular reactions in black tattoos as markers of sarcoidosis: study of 92 tattoo reactions from a hospital material,” Dermatology, vol. 232, no. 6, pp. 679–686, 2017. View at Publisher · View at Google Scholar
  16. J. Cotliar, C. Querfeld, W. J. Boswell, N. Raja, D. Raz, and R. Chen, “Pembrolizumab-associated sarcoidosis,” JAAD Case Reports, vol. 2, no. 4, pp. 290–293, 2016. View at Publisher · View at Google Scholar
  17. S. Le Burel, S. Champiat, C. Mateus et al., “Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis,” European Journal of Cancer, vol. 82, pp. 34–44, 2017. View at Publisher · View at Google Scholar
  18. A. J. Lomax, H. M. McGuire, C. McNeil et al., “Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis,” International Journal of Rheumatic Diseases, vol. 20, no. 9, pp. 1277–1285, 2017. View at Publisher · View at Google Scholar
  19. E. Oommen and J. Allam, “Ipilimumab lung toxicity,” CHEST, vol. 152, no. 4, Article ID A724, 2017. View at Publisher · View at Google Scholar
  20. S. B. Reddy, J. D. Possick, H. M. Kluger, A. Galan, and D. Han, “Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma,” Journal of Immunotherapy, vol. 40, no. 8, pp. 307–311, 2017. View at Publisher · View at Google Scholar
  21. A. Toumeh, R. Sakhi, S. Shah, S. K. Arudra, L. E. De Las Casas, and R. T. Skeel, “Ipilimumab-induced granulomatous disease occurring simultaneously with disease progression in a patient with metastatic melanoma,” American Journal of Therapeutics, vol. 23, no. 4, pp. e1068–e1071, 2016. View at Publisher · View at Google Scholar
  22. N. Yatim, C. Mateus, and P. Charles, “Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission,” La Revue de Médecine Interne, vol. 39, no. 2, pp. 130–133, 2018. View at Publisher · View at Google Scholar
  23. B. Firwana, R. Ravilla, M. Raval, L. Hutchins, and F. Mahmoud, “Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors,” Journal of Oncology Pharmacy Practice, vol. 23, no. 8, pp. 620–624, 2017. View at Publisher · View at Google Scholar
  24. F.-X. Danlos, C. Pagès, B. Baroudjian et al., “Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma,” Chest, vol. 149, no. 5, pp. e133–e136, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Martínez Leboráns, A. Esteve Martínez, A. M. Victoria Martínez, V. Alegre de Miquel, and A. Berrocal Jaime, “Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy,” Dermatologic Therapy, vol. 29, no. 5, pp. 306–308, 2016. View at Publisher · View at Google Scholar
  26. C. Tissot, A. Carsin, N. Freymond, Y. Pacheco, and G. Devouassoux, “Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy,” European Respiratory Journal, vol. 41, no. 1, pp. 246-247, 2012. View at Publisher · View at Google Scholar
  27. R. B. Reule and J. P. North, “Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab,” Journal of the American Academy of Dermatology, vol. 69, no. 5, pp. e272–e273, 2013. View at Publisher · View at Google Scholar
  28. M. C. McKenna, K. Molloy, S. Crowther et al., “Pembrolizumab-related sarcoid-like reaction presenting as reactivation of quiescent scars,” Journal of Oncology Practice, vol. 14, no. 3, pp. 200-201, 2018. View at Publisher · View at Google Scholar
  29. H. Jespersen, S. Bjursten, L. Ny, and M. Levin, “Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases,” The Lancet Oncology, vol. 19, no. 6, Article ID e327, 2018. View at Publisher · View at Google Scholar
  30. S. Burillo-Martinez, C. Morales-Raya, M. Prieto-Barrios, J. Rodriguez-Peralto, and P. Ortiz-Romero, “Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum,” JAMA Dermatology, vol. 153, no. 7, pp. 721-722, 2017. View at Publisher · View at Google Scholar
  31. L. Paolini, C. Poli, S. Blanchard et al., “Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment,” Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, p. 52, 2018. View at Publisher · View at Google Scholar
  32. S. Wilgenhof, V. Morlion, A. C. Seghers et al., “Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor,” Anticancer Reseach, vol. 32, no. 4, pp. 1355–1359, 2012. View at Google Scholar · View at Scopus
  33. W. M. Timmermans, J. A. van Laar, P. M. van Hagen, and M. C. van Zelm, “Immunopathogenesis of granulomas in chronic autoinflammatory diseases,” Clinical & Translational Immunology, vol. 5, no. 12, Article ID e118, 2016. View at Publisher · View at Google Scholar
  34. S. N. Georas, T. J. Chapman, and E. D. Crouser, “Sarcoidosis and T-helper cells. Th1, Th17, or Th17.1?” American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 11, pp. 1198–1200, 2016. View at Publisher · View at Google Scholar
  35. J. Ramstein, C. E. Broos, L. J. Simpson et al., “IFN-gamma-producing T-helpr 17.1 cells are increased in sarcoidosis andare moreprevalent than T-helper type 1 cells,” American Journal of Respiratory and Critical Care Medicine, vol. 193, pp. 1281–1291, 2016. View at Google Scholar